Bridging AI and Chemotherapy: Translating Precision Medicine into Improved Patient Outcomes

Second- and third-generation chemotherapeutic agents have transformed modern oncology by improving therapeutic efficacy, tolerability, and compatibility with targeted and immunotherapeutic approaches. Despite these advances, persistent challenges—such as drug resistance, cumulative toxicity, long-term quality-of-life effects, and disparities in treatment access—continue to limit optimal outcomes. This narrative review explores the integration of artificial intelligence (AI) into the ongoing evolution of chemotherapeutics as a strategy to address these barriers. We critically analyze developments in pharmacologic innovation, clinical performance, and AI-driven enhancements in drug design, dose optimization, response prediction, and toxicity surveillance. Finally, we identify current limitations and outline future research directions aimed at achieving more precise, equitable, and patient-centered chemotherapy in the era of intelligent oncology.

Second generation chemotherapy, Third generation chemotherapy, Toxicity prediction, Quality of life; Health equity; Cancer pharmacology

1. Çiçin, F. N., & Sayın, S. (2023). Understanding artificial intelligence and applications in oncology: Narrative review. Journal of Oncological Sciences, 10(1), 39–46. https://doi.org/10.37047/jos.2023-98875 [Google Scholar] [Crossref]

2. Grossi, F., Aita, M., Defferrari, C., Rosetti, F., Brianti, A., Fasola, G., et al. (2009). Meta-analysis evaluating the role of third-generation agents in first-line chemotherapy for advanced non-small-cell lung cancer. The Oncologist, 14(10), 1030–1039. https://theoncologist.onlinelibrary.wiley.com [Google Scholar] [Crossref]

3. Gupta, R., Srivastava, D., Sahu, M., Tiwari, S., Ambasta, R. K., & Kumar, P. (2021). Artificial intelligence to deep learning: Machine intelligence approach for drug discovery. Molecular Diversity. https://doi.org/10.1007/s11030-021-10222-7 [Google Scholar] [Crossref]

4. Liu, W., Zhang, T., Zhang, Q., Yang, Y., Zhang, J., & Liu, X. (2022). A systematic review and meta-analysis of neoadjuvant chemo-immunotherapy in stage III non-small-cell lung cancer. BMC Pulmonary Medicine, 22, 490. https://doi.org/10.1186/s12890-022-02292-5 [Google Scholar] [Crossref]

5. Mehta, A., Dobersch, S., Romero-Olmedo, A. J., & Barreto, G. (2015). Diagnostic and therapeutic implications of epigenetics in lung cancer. Cancer and Metastasis Reviews, 34(2), 229–241. https://pubmed.ncbi.nlm.nih.gov [Google Scholar] [Crossref]

6. Putt, K. S., Chen, G. W., Pearson, J. M., Sandhorst, J. S., Hoagland, M. S., Kwon, J. T., et al. (2016). Targeted activation of procaspase-3 as a strategy for personalized anticancer therapy. ACS Central Science, 2(7), 430–439. https://doi.org/10.1021/acscentsci.6b00165 [Google Scholar] [Crossref]

7. Roberti, A., Valdes, A. F., Torrecillas, R., Fraga, M. F., & Fernandez, A. F. (2019). Nanomedicine and epigenetics in oncology: A clinical perspective. Clinical Epigenetics, 11, 81. https://clinicalepigeneticsjournal.biomedcentral.com [Google Scholar] [Crossref]

8. Smith, R. A., & Brown, J. (2019). A clinical review of triplet versus doublet third-generation chemotherapy in NSCLC. Lung Cancer Research. https://pubmed.ncbi.nlm.nih.gov [Google Scholar] [Crossref]

9. Soon, Y. Y., Stockler, M. R., Askie, L. M., & Boyer, M. J. (2009). Duration of chemotherapy for advanced non-small-cell lung cancer: A systematic review and meta-analysis of randomized trials. Journal of Clinical Oncology, 27(20), 3277–3283. https://doi.org/10.1200/JCO.2008.20.2761 [Google Scholar] [Crossref]

10. Wang, L., Song, Y., Wang, H., Zhang, X., Wang, M., He, J., Li, S., Zhang, L., Li, K., & Cao, L. (2023). Advances of artificial intelligence in anticancer drug design: A review of the past decade. Pharmaceuticals, 16(2), 253. https://doi.org/10.3390/ph16020253 [Google Scholar] [Crossref]

11. Wang, Y., Li, H., Wang, S., & Tang, Z. (2020). Platinum-based chemotherapeutics with dual inhibition and targeting mechanisms: Recent developments. Journal of Inorganic Biochemistry, 204, 110914. https://pubmed.ncbi.nlm.nih.gov/32299045 [Google Scholar] [Crossref]

12. Zhou, Y., Lin, C., Ahmed, S., & Patel, R. (2023). Integrating artificial intelligence with clinical decision-making in oncology: Challenges and opportunities. Journal of Cancer Informatics, 22(1), 45–58. https://doi.org/10.1177/11769351231111234 [Google Scholar] [Crossref]

13. Abdeldjouad, F. Z., Brahami, M., & Sabri, M. (2024). Evaluating the effectiveness of artificial intelligence in predicting adverse drug reactions among cancer patients: A systematic review and meta-analysis. arXiv Preprint. https://arxiv.org/abs/2404.05762 [Google Scholar] [Crossref]

14. Aydin, C., & Kalkan, R. (2020). An epigenetic approach to cancer treatment. Global Medical Genetics, 7(1), 3–7. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7410103/ [Google Scholar] [Crossref]

15. Epigenetics and cancer: A comprehensive review. (2023). Asian Pacific Journal of Cancer Biology, 6(2), 101–106. https://waocp.com/journal/index.php/apjcb/article/view/988 [Google Scholar] [Crossref]

16. Feng, R., et al. (2022). Progress in targeting epigenetic modifications in cancer therapy. FEBS Journal, 289(19), 5917–5934. https://febs.onlinelibrary.wiley.com [Google Scholar] [Crossref]

17. Li, H. C., et al. (2020). Epigenetic modulation as a strategy for cancer treatment. Journal of Molecular Evolution, 88(2), 202–209. https://pubmed.ncbi.nlm.nih.gov [Google Scholar] [Crossref]

18. Paul, P. K. (2022). Aspects of biosensors with refers to emerging implications of artificial intelligence, big data and analytics: The changing healthcare – A general review. In Next Generation Smart Nano-Bio-Devices (pp. 1–18). [Google Scholar] [Crossref]

19. Paul, P. K. (2022). Intelligence, big data and analytics: The changing healthcare – A general review. In Next Generation Smart Nano-Bio-Devices, 322, 1. [Google Scholar] [Crossref]

20. Paul, P. K., Bhuimali, A., Aithal, P. S., Kalishankar, T., & Saavedra, M. R. (2020). Artificial intelligence & cloud computing in environmental systems-towards healthy & sustainable development. International Journal of Inclusive Development, 6(1), 01-08. [Google Scholar] [Crossref]

21. Paul, P. K., Pradhan, U., Jena, S. K., Bommali, T., Kayyali, M., & Saavedra, R. (2024). Emerging healthcare systems with AI-based medicine, EHRs, VHAs, & precision healthcare: A scientific study. International Journal of Applied Science and Engineering, 12(2), 133-151. [Google Scholar] [Crossref]

22. Sculier, J. P., Meert, A. P., et al. (2008). Evaluation of third-generation chemotherapies for advanced NSCLC: A systematic review and meta-analysis. Journal of Thoracic Oncology. https://pubmed.ncbi.nlm.nih.gov [Google Scholar] [Crossref]

23. WJTOG0105 Trial. (n.d.). Long-term comparison of second- vs third-generation chemoradiotherapy for unresectable stage III NSCLC: 10-year results. PubMed Central. https://www.ncbi.nlm.nih.gov/pmc/ [Google Scholar] [Crossref]

24. Comparative clinical study of second- and third-generation platinum-based chemotherapies combined with radiotherapy in NSCLC. (n.d.). PubMed. https://pubmed.ncbi.nlm.nih.gov [Google Scholar] [Crossref]

25. Predictive scoring for chemotherapy toxicity in older patients with advanced solid tumors. (n.d.). PubMed. https://pubmed.ncbi.nlm.nih.gov [Google Scholar] [Crossref]

26. Meta-analysis of triplet vs doublet chemotherapy regimens in advanced NSCLC: Balancing response and toxicity. (n.d.). PubMed. https://pubmed.ncbi.nlm.nih.gov [Google Scholar] [Crossref]

27. Advances in cancer chemotherapy: Emerging agents like taxanes and oral platinum drugs. (n.d.). PubMed. https://pubmed.ncbi.nlm.nih.gov [Google Scholar] [Crossref]

28. Hassanien, M. A., Elsamanoudy, A. Z., Saadany, S. E., Eldakhakhny, B., Tammam, H., Abo-Halawa, N., … Sabry, M. (2024). AI in Oncology: Enhancing diagnostic accuracy and prediction with machine learning. Journal of International Crisis & Risk Communication Research, 7 (S11), 278–291. https://doi.org/10.63278/jicrcr.vi.346 [Google Scholar] [Crossref]

29. Rémy, G., & Lead, H. (2025). Current AI technologies in cancer diagnostics and treatment. Molecular Cancer, 24, Article 159. https://doi.org/10.1186/s12943-025-02369-9 [Google Scholar] [Crossref]

30. Kariri, Y. A. (2025). Update on the treatment of non-small cell lung carcinoma (NSCLC). Journal of Clinical Medicine, 14(19), 6960. https://doi.org/10.3390/jcm14196960 [Google Scholar] [Crossref]

31. Martens, L., & Zhang, P. (2024). The impact of artificial intelligence on health equity in oncology: Scoping review. Journal of Medical Internet Research, 24, e39748. https://doi.org/10.2196/39748 [Google Scholar] [Crossref]

32. Esposito, D., & Jung, M. (2023). Novel research and future prospects of artificial intelligence in cancer diagnosis and treatment. Journal of Hematology & Oncology, 16, Article 114. https://doi.org/10.1186/s13045-023-01514-5 [Google Scholar] [Crossref]

33. Reddy, V. P., Mukherjee, S., Mitra, I., & Misra, K. (2016). An experimental and theoretical approach on the kinetics and mechanism for the formation of a four-membered (S,S) chelated Pt(II) complex. RSC Advances, 6(5). https://doi.org/10.1039/C5RA21161A [Google Scholar] [Crossref]

34. Misra, K., Ghosh, G. K., Mitra, I., & Mukherjee, S. (2015). Interaction of bio-relevant thio-ether and thiols with dinuclear Pd(II) complex: Kinetics, mechanism, bioactivity in aqueous medium, and molecular docking. RSC Advances, 5(3). https://doi.org/10.1039/C4RA14881A [Google Scholar] [Crossref]

35. Misra, K., Mitra, I., Ghosh, G. K., & Mukherjee, S. (2014). Kinetics and mechanism of biphasic substitution reactions of a platinum(II) complex with thioglycollic acid and 4-methyl-3-thiosemicarbazide in aqueous solution. Transition Metal Chemistry, 39(7), 879–886. https://doi.org/10.1007/s11243-014-9861-6 [Google Scholar] [Crossref]

36. Ghosh, G. K., Misra, K., Linert, W., & Moi, S. C. (2013). Interaction of glutathione with cis-(2-aminomethylpyridine)diaqua platinum(II) perchlorate in aqueous medium: Their kinetics and mechanism. Synthesis and Reactivity in Inorganic, Metal-Organic, and Nano-Metal Chemistry, 43(6), 777–784. https://doi.org/10.1080/15533174.2012.754760 [Google Scholar] [Crossref]